New RSV vaccine aims to shield adults from severe respiratory infection
NCT ID NCT07653100
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental vaccine called RSVpreF in adults to see if it is safe and triggers a strong immune response against respiratory syncytial virus (RSV). Around 540 adults in India will receive either the vaccine or a placebo. Researchers will monitor for side effects and measure antibody levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RSVpreF vaccine
What this could lead to
If successful, this vaccine could help protect adults from severe RSV infections, reducing hospitalizations and serious respiratory illness.
What could go wrong
This is a phase 3 trial focused on safety and immune response, not yet proven to prevent disease. Side effects like injection-site reactions or fever are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aakash Healthcare Private Limited
Dwarka, National Capital Territory of Delhi, 110075, India
-
BGS Global Institute of Medical Sciences (BGSGIMS)
Bangalore, Karnataka, 560060, India
-
King George Hospital
Visakhapatnam, Andhra Pradesh, 530002, India
-
Maharaja Agrasen Superspeciality Hospital
Jaipur, Rajasthan, 302039, India
-
Radhakrishna Multispeciality Hospital and IVF Center
Bangalore, Karnataka, 560085, India